Is heart failure different on the two continents (North America and Europe)?

Current Cardiology Reports

Volumn 6, Issue 3, 2004, Pages 182-188

  Hughes Doichev, Rachel ^b   Dunlap, Mark E ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; ETANERCEPT; METOPROLOL; MOXONIDINE; OMAPATRILAT; SPIRONOLACTONE;

AGING; ANEMIA; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EUROPE; EXERCISE; FAMILY HISTORY; GENDER; GENE THERAPY; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; LIFESTYLE; LUNG DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; MYOCARDITIS; NORTH AMERICA; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SAMPLE SIZE; SYSTOLE; VALVULAR HEART DISEASE; CLINICAL PRACTICE; COMPLICATION; SEX DIFFERENCE;

EUROPE; HEART FAILURE; HUMANS; HYPERTENSION; NORTH AMERICA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SEX FACTORS;

EID: 3142691897     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0021-z     Document Type: Review

References (53)

1. Klainer LM, Gibson TC, White KL: The epidemiology of cardiac failure. H Chronic Dis 1965, 18:797-781.
2. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2002.
3. Klein L, O'Connor M, Gattis WA, et al.: Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003, 91(Suppl):18F-40F.
4. Maisel WH, Stevenson LW: Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am J Cardiol 2003, 91(Suppl):2D-8D.
5. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
6. Redfield MM: Heart failure an epidemic of uncertain proportions. N Engl J Med 2002, 347:1442-1444.
7. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
8. McCullough PA, Philibin EF, Spertus JA, et al.: Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study. J Am Coll Cardiol 2002, 39:60-69.
9. Ho KK, Anderson KM, Kannel WB, et al.: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993, 88:107-115.
10. Krum H, Gilbert RE: Demographics and concomitant disorders in heart failure. Lancet 2003, 362:147-158.
11. Jong P, Vowinckel E, Liu PP, et al.: Prognosis and determinant of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002, 162:689-1694.
12. Scott RL: Is heart failure in African Americans a distinct entity? CHF 2003, 9:193-196.
13. Heiat A, Gross CP, Krumholz HM: Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002, 162:1682-1688.
14. Remme WJ, Swedberg K: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001, 22:1527-1560.
15. Cleland JG, Cohen-Solal A, Aguilar JC, et al.: Management of heart failure in primary care (the IMPROVEMENT of heart failure programme): an international survey. Lancet 2002, 360:1631-1639.
16. Parameshwar J, Shackell MM, Richardson A, et al.: Prevalence of heart failure in three general practices in northwest London. Br J Gen Pract 1992, 42:287-289.
17. Wheeldon NM, MacDonald TM, Flucker CJ, et al.: Echocardiography in chronic heart failure. Q J Med 1993, 86:17-23.
18. Opasich C, De Giuli F, Majani G, et al.: Current perspectives. Heart failure woman: does she make any difference? Ital Heart J 2003, 4:4-16.
19. Remes J, Reunanen A, Aromaa AA, Pyorala K: Incidence of heart failure in Eastern Finland: a population based surveillance study. Eur Heart J 1992:13:588-593.
20. Stewart S, MacIntyre K, Capewell S, McMurray JJ: Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003, 89:49-53.
21. Westert GP, Lagoe RJ, Keskimaki I, et al.: An international study of hospital readmission and related utilization in Europe and the USA. Health Policy 2002, 61:269-278.
22. Fonarow GC, Horwich TB: Prevention of heart failure: effective strategies to combat the growing epidemic. Rev Cardiovasc Med 2003, 4:8-17.
23. Lewis EF, Moye LA, Rouleau JL, et al.: Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 2003, 42:1446-1453.
24. Hellerman JP, Goraya TY, Jacobsen SJ, et al.: Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol 2003, 157:1101-1107.
25. Bell DS: Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003, 26:2433-2441.
26. Amato L, Paolisso G, Cacciatore F, et al.: Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly: the Osservatorio Geriatico Regione Campania group. Diabetes Metab 1997, 23:213-218.
27. Kannel SB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 1979, 241:2035-2038.
28. Nichols GA, Hillier TA, Erby JR, Brown JB: Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001, 24:1614-1619.
29. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003, 362:777-781.
30. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003, 362:767-771.
31. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003, 362:759-766.
32. Granger CB, McMurray JJ, Yusuf S, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors, the CHARM-alternative trial. Lancet 2003, 262:772-776.
33. Poole-Wilson PA, Swedberg K, Cleland JG, et al.: comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 2003, 362:7-13.
34. McMurray J, Ostergren J, Pfeffer M, et al.: Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003, 5:261-270.
35. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left biventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
36. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987, 316:1429-1435.
37. Stewart S, McIntyre K, Capewell S, McMurray JJ: Heart failure in a cold climate. Seasonal variation in heart failure-related morbidity and mortality. J Am Coll Cardiol 2002, 39:760-766.
38. Kulig M, Erika S, Norbert WS: Comparing methodological quality and consistency of international guidelines for the management of patients with chronic heart failure. Eur J Heart Fail 2003, 5:327-335.
39. Burkhoff D, Maurer MS, Packer M: Heart failure with a normal ejection fraction: is it really a disorder of diastolic function? Circulation 2003, 107:656-658.
40. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107:714-720.
41. Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107:659-663.
42. Bradley TD, Floras JS: Sleep apnea and heart failure: part I: obstructive sleep apnea. Circulation 2003, 107:1671-1678.
43. Shahar E, Whitney CW, Redline S, et al.: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the sleep heart health study. Am J Resp Crit Care Med 2001, 163:19-25.
44. Bradley TD, Logan AG, Floras JS, and the CANPAP Investigators: Rationale and design of the Canadian Continuous Positive Airway Pressure Trial for Congestive Heart Failure patients with Central Sleep Apnea - CANPAP. Can J Cardiol 2001 17:677-684.
45. Bradley TD, Flora JS: Sleep apnea and heart failure: part II: central sleep apnea. Circulation 2003, 107:1822-1826.
46. McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure: part I. Circulation 2002, 105:2099-2106.
47. Mehra M, Uber PA, Francis GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol 2003, 41:1606-1610.
48. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
49. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
50. Komajda M, Follath F, Swedberg K, et al.:and the Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The Euroheart failure survey programme a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 2003, 24:464-475.
51. Saxon, LA, Ellenbogen KA: Resynchronization therapy for the treatment of heart failure. Circulation 2003, 108:1044-1048.
52. Francis GS, Tang WH: Pathophysiology of congestive heart failure. Rev Cardiovasc Med 2003, 4(Suppl 2):S14-S20.
53. Baliga RR, Narula J: Pharmacogenomics of congestive heart failure. Med Clin North Am 2003, 87:569-578.